IL-BAI
8.12.2022 19:43:43 CET | Business Wire | Press release
BAI, a nonprofit independent organization that delivers the most actionable insights in financial services, has named ten organizational winners and one honorable mention for the 2022 BAI Global Innovation Awards. Ten individuals were also named BAI Rising Stars. The awards are the industry’s leading program celebrating achievements in innovation, such as pursuing bold solutions for improving customer experience; implementing advanced technologies; and improving the lives of employees, customers, and communities.
Winners were selected by the BAI Innovation Circle, a panel of distinguished judges from around the world who are at the forefront of innovation in the financial services sector. Collectively, the winners represent outstanding contributions by teams and individuals and showcase inspiration from around the world. These global trailblazers have successfully designed and delivered innovations that positively improved customer relationships and served their communities in powerful ways.
“Innovation is a significant driver of the impact that successful financial services companies have on their customers and communities. The industry continues to bring powerful new approaches and solutions to better meet customer needs in new and different ways,” said Debbie Bianucci, president and CEO of BAI and Innovation Circle Judge. “The companies and individuals recognized this year were particularly creative and focused on addressing practical issues that made meaningful improvements for customers and employees.”
The 2022 BAI Global Innovation Award Winners and Honorable Mention are:
Banco Popular (Puerto Rico)
Innovation in Learning & Development
Innovation: Talent Lab & Skills Accelerator
Bank of America (USA)
Innovation in Digital Security
Innovation: Bank of America Security Center
Dreams Technology (United Kingdom)
Innovation in Digital Financial Planning
Innovation: Dreams ESG Innovation
Growsari (Philippines)
Innovation in Digital Commercial Financing
Innovation: GROWSARI.com, Powering the Digital Economy of the Philippines
Money Management International, Inc. (USA)
Innovation in Community Disaster Recovery
Innovation: Project Porchlight by MMI
MVB Bank (USA)
Innovation in Commercial Banking Onboarding Experience
Innovation: Onboarding Fintechs Better, Faster, Stronger…The Victor (ad)Vantage
Payten Teknoloji A.S.-Paratika (Turkey)
Innovation in Payments
Innovation: Paratika Crowdfunding e-Payment Project
Standard Bank (South Africa)
Innovation in Community Sustainability
Innovation: One Farm Share
TIAA (USA)
Innovation in Fraud Prevention
Innovation: TIAA Phone Authentication Risk Management (PARM)
Union Bank of India (India)
Innovation in HR Transformation
Innovation: Union Prerna
BMO (USA)
Innovation in Diversity, Equity & Inclusion (Honorable Mention)
Innovation: True Name
To further recognize innovation in financial services, a new award was established in 2022 to recognize individual leaders. The BAI Rising Star Award honors individuals who are up-and-coming leaders in financial services innovation. Leaders were nominated by their organizations and the recipients of the BAI Rising Star Award were selected based on their impact on and passion for innovation and their ability to drive positive change in their organizations.
The 2022 BAI Rising Star Award Winners are:
Sachin Chandna (United Arab Emirates), SVP, Head of Customer Intelligence & Engagement – Emirates NBD
Geoff Ellis (USA), Senior Director Application Development – Ally Financial
Ashley Fiore (USA), Chief Business Intelligence Officer – KlariVis
Snigdha Kumar (USA), Head of Product Operations – Digit
Larricia Lumpkins (USA), SVP, Senior Strategy Manager – Citizens Financial Group
Niki Neumann (South Africa), Executive, Lead Ecosystem Agriculture – Standard Bank Group
Dr. Chetna Pandey (India), Deputy General Manager – Union Bank of India
Stacy Regnier (USA), SVP, Retail Strategic Programs and Business Transformation – Commerce Bank
Bradwin Roper (South Africa), CEO – FNB Connect
Paul Whelpton (South Africa), Group Analytics Officer and Group Head of Trading – JUMO
For more information about the winners and their innovations, visit https://www.bai.org/globalinnovations/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom